SCHEDULE: Alafi Capital Discloses Warrant Holdings in CalciMedica

Alafi Capital Company LLC and Christopher D. Alafi have filed an amendment to their Schedule 13D, reporting the receipt of new warrants in CalciMedica, Inc. following stockholder approval.

Summary

• Alafi Capital Company LLC and Christopher D. Alafi have filed an amendment (Amendment No. 1) to their Schedule 13D regarding their holdings in CalciMedica, Inc.
• The amendment was triggered by the issuance of warrants to the Reporting Persons on August 19, 2026, after receiving Stockholder Approval.
• Alafi Capital Company LLC now beneficially owns 7,220,101 shares, representing 19.9% of CalciMedica's common stock.
• This ownership includes 5,112,345 directly held shares and various warrants.
• Christopher D. Alafi also beneficially owns 7,220,101 shares, representing 19.9% of the class.
• The reported ownership for both entities includes specific warrants: 130,651 at $7.15, 923,227 at $0.8033, and 923,227 at $1.00.
• The filing notes that certain Series A and Series B warrants (2,605,965 each) are not currently exercisable due to a 19.99% beneficial ownership limitation.
• The percentage ownership calculation is based on 34,141,460 shares outstanding as of August 20, 2026, plus the total possible exercisable warrants.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, primarily reflecting an administrative update on warrant issuance rather than significant operational or financial performance changes.

Positives

• Receipt of new warrants indicates potential for increased equity stake in CalciMedica, Inc.
• The issuance of warrants was approved by stockholders, suggesting alignment with shareholder interests.
• The reporting persons maintain a significant beneficial ownership of 19.9%, demonstrating continued strategic interest in the company.

Negatives

• Some warrants (Series A and B) are not currently exercisable due to ownership limitations, capping immediate influence or potential gains.
• The filing does not provide details on the financial performance or strategic progress of CalciMedica, Inc., focusing solely on ownership changes.

Risks

• The 19.99% beneficial ownership limitation on Series A and Series B warrants restricts the ability to increase stake beyond this threshold without further action or waiver.
• The value and exercisability of the warrants are subject to the future performance and stock price of CalciMedica, Inc.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding CalciMedica, Inc.'s future performance. The outlook is tied to the potential exercise of warrants and the company's future stock performance.

Management Comments

• Alafi Capital Company LLC and Christopher D. Alafi disclaim beneficial ownership of shares except to the extent of their pecuniary interest, and except for shares held of record.
• The filing is an amendment to report the receipt of Series A and Series B Warrants following Stockholder Approval.

Industry Context

StockSavvy.ai notes that the issuance and reporting of warrants are common in the biotechnology and pharmaceutical sectors, often used as financing tools or incentives. This filing reflects a standard disclosure requirement for significant beneficial ownership changes.

Stakeholder Impact

• Shareholders: The issuance of warrants could potentially dilute existing shareholders if exercised, but also signifies continued investor confidence and potential for future capital infusion.
• Investors: The filing provides transparency on significant warrant holdings, impacting the understanding of potential future share supply and ownership structure.

Next Steps

• The Reporting Persons may exercise their warrants based on market conditions and the performance of CalciMedica, Inc.
• Further filings may be required if beneficial ownership changes significantly.

Key Dates

Keywords

CalciMedica, Alafi Capital, Schedule 13D, Warrants, Beneficial Ownership, Stockholder Approval, Equity